Visfatin levels in female, morbid, nondiabetic obese patients after biliopancreatic diversion surgery

Surg Obes Relat Dis. 2011 Mar-Apr;7(2):195-8. doi: 10.1016/j.soard.2010.08.008. Epub 2010 Aug 26.

Abstract

Background: Visfatin was recently identified as a protein preferentially expressed in visceral adipose tissue. The purpose of the present study was to investigate the changes in serum visfatin levels after biliopancreatic diversion and the association of the changes observed with other parameters in morbidly nondiabetic obese women.

Methods: A sample of 27 morbidly obese women (body mass index >40 kg/m(2)) were operated. The biochemical and anthropometric parameters were measured at the initial visit and 1 year after surgery. The frequency of patients with hypertension and hyperlipidemia was recorded at 1 year.

Results: The mean patient age was 46.0 ± 13.0 years, and the mean preoperative body mass index was 46.3 ± 13.1 kg/m(2). The body mass index, weight, waist circumference, fat mass, blood pressure, total cholesterol, and low-density lipoprotein cholesterol had decreased significantly. The visfatin levels did not change after surgery (5.70 ± 1.84 ng/mL versus 6.12 ± 1.68 ng/mL; P = NS). The correlation analysis showed a positive association between the baseline visfatin and total cholesterol level (r = 0.49; P <.01).

Conclusion: The massive weight reduction 1 year after biliopancreatic diversion was not associated with a significant change in the circulating visfatin levels in morbidly obese women.

Publication types

  • Comparative Study

MeSH terms

  • Biliopancreatic Diversion / adverse effects*
  • Biomarkers / blood
  • Body Mass Index
  • Diabetes Mellitus
  • Disease Progression
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Follow-Up Studies
  • Humans
  • Intra-Abdominal Fat / metabolism
  • Middle Aged
  • Nicotinamide Phosphoribosyltransferase / biosynthesis
  • Nicotinamide Phosphoribosyltransferase / blood*
  • Obesity, Morbid / blood
  • Obesity, Morbid / surgery*
  • Postoperative Period
  • Prospective Studies
  • Severity of Illness Index
  • Time Factors

Substances

  • Biomarkers
  • Nicotinamide Phosphoribosyltransferase